Screening Activities Clause Samples

The Screening Activities clause defines the procedures and requirements for conducting background checks or other vetting processes on individuals or entities involved in an agreement. Typically, this clause outlines the types of screenings permitted, such as criminal background checks, credit checks, or verification of qualifications, and may specify who is responsible for performing them and under what circumstances. Its core practical function is to ensure that all parties meet certain standards or criteria before engaging in a contractual relationship, thereby reducing risk and promoting trust between the parties.
Screening Activities. During the Research Term, each party shall respectively make all Program Assays available for the Research Program. In the event that either party develops or acquires new Program Assays during the Research Term, such party shall promptly inform the Research Committee of the existence of such Program Assay. Unless otherwise directed by the Research Committee, Tularik shall conduct all screening of the Program Substances. To the extent practicable, the Program Substances shall be screened contemporaneously in Program Assays for both the Core Targets and Option Targets. Tularik shall notify Merck promptly when a Program Substance demonstrates Anti-Viral Activity in a Core Target or Option Target. Any Program Substance which does not demonstrate Anti-Viral Activity in a Core Target or Option Target shall be returned to the party which supplied such Program Substance, and shall not be included further under the terms of the Agreement.
View SourceView Similar (3)
Screening Activities. The Screening Activities shall consist of a series of activities as outlined in the Screening Plan to determine if a Candidate Compound meets the PoC Criteria. Screening Activities may include screening for and identifying (i) a Strain which produces the Candidate Compound or (ii) a Strain having a specific character or trait. It is expected that Screening Activities as outlined in each Screening Plan will take an average of eight (8) weeks (or potentially longer in the case of New Technology Activities), which may vary depending on the complexity of the Screening Activities in the Screening Plan. The Parties acknowledge that a Screening Activity may require subprojects, particularly in the case of the New Technology Activities, and in such events subprojects shall, for clarity, be considered part of the applicable Screening Activities.
View SourceView Similar (3)
Screening Activities. Juneau shall be responsible, directly or indirectly through one or more persons reasonably acceptable to Predictive, for conducting the screening and billing services with respect to specimens properly submitted through use of the Licensed Assay promoted, marketed and distributed by Predictive. In the event that Predictive acquires a CLIA lab the parties will use the Predictive lab to perform such services unless it is not commercially reasonable to do so as determined by the parties. In no event will Juneau be required to provide in any calendar quarter a volume of services related to the Licensed Assay in excess of 125% of Predictive’s Sales Forecast for such quarter made pursuant to Section 2.2(c).
View Source
Screening Activities. For each Discovery Research Program, Kronos shall conduct screening activities pursuant to the Discovery Research Plan, with the objective of [***] set forth in the Discovery Research Plan (each such compound, a “Screening Hit”; such activities, collectively, the “Screening Activities”). Kronos shall provide the results and any data generated pursuant to the Screening Activities on an ongoing basis to the JPT within any timelines related thereto as agreed to by the JPT.
View Source
Screening Activities 
View SourceView Similar (2)

Related to Screening Activities

  • Marketing Activities The Borrower will not, and will not permit any of its Subsidiaries to, engage in marketing activities for any Hydrocarbons or enter into any contracts related thereto other than (i) contracts for the sale of Hydrocarbons scheduled or reasonably estimated to be produced from their proved Oil and Gas Properties during the period of such contract, (ii) contracts for the sale of Hydrocarbons scheduled or reasonably estimated to be produced from proved Oil and Gas Properties of third parties during the period of such contract associated with the Oil and Gas Properties of the Borrower and its Subsidiaries that the Borrower or one of its Subsidiaries has the right to market pursuant to joint operating agreements, unitization agreements or other similar contracts that are usual and customary in the oil and gas business and (iii) other contracts for the purchase and/or sale of Hydrocarbons of third parties (A) which have generally offsetting provisions (i.e. corresponding pricing mechanics, delivery dates and points and volumes) such that no “position” is taken and (B) for which appropriate credit support has been taken to alleviate the material credit risks of the counterparty thereto.

  • Monitoring Activities The Cheyenne MPO shall have the right to monitor all activities related to this Agreement that are performed by the Consultant or its subconsultants. This shall include, but not be limited to, the right to make site inspections at any time and with reasonable notice; to bring experts and consultants on site to examine or evaluate completed work or work in progress; to examine the books, ledgers, documents, papers, and records pertinent to this Agreement; and to observe personnel in every phase of performance of the related work.

  • Regulatory Activities a) As between the Parties, Xynomic shall have the sole responsibility and discretion for preparing, obtaining, and maintaining Drug Approval Applications (including the setting of the overall regulatory strategy therefor), other Regulatory Approvals and other submissions, and for conducting communications with the Regulatory Authorities, for Licensed Compounds or Licensed Products in the Territory (which shall include filings of or with respect to INDs and other filings or communications with the Regulatory Authorities). All Regulatory Approvals relating to the Licensed Compounds or Licensed Products with respect to the Territory shall be owned by, and shall be the sole property and held in the name of, Xynomic or its designated Affiliate. Pharmacyclics hereby assigns to Xynomic all of Pharmacyclics’ (or its Affiliates’) right, title, and interest in and to all Regulatory Documentation owned by Pharmacyclics (or its Affiliates) and held in Pharmacyclics’ name (or its Affiliates) as of the Effective Date or generated in the “winding up” activities after the Effective Date and shall deliver all Regulatory Documentation as well as embodiments of all Regulatory Documentation to Xynomic within sixty (60) days after the Effective Date. b) Xynomic shall notify the Pharmacyclics Alliance Manager promptly (but in no event later than forty-eight (48) hours) following its determination that any event, incident, or circumstance has occurred that may result in the need for a recall, market suspension, or market withdrawal of a Licensed Compound or Licensed Product in the Territory, and shall include in such notice the reasoning behind such determination, and any supporting facts. Xynomic (or its Sublicensee) shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension, or market withdrawal in the Territory; provided that prior to any implementation of such a recall, market suspension, or market withdrawal, Xynomic shall consult with Pharmacyclics and shall consider Pharmacyclics’ comments in good faith. If a recall, market suspension, or market withdrawal is mandated by a Regulatory Authority in the Territory, Xynomic (or its Sublicensee) shall initiate such a recall, market suspension, or market withdrawal in compliance with Applicable Law. For all recalls, market suspensions, or market withdrawals undertaken pursuant to this Section 2.2.1.b), Xynomic (or its Sublicensee) shall be solely responsible for the execution and all costs thereof.

  • Competing Activities Notwithstanding any duty otherwise existing at law or in equity, (i) neither a Member nor a Manager of the Company, or any of their respective affiliates, partners, members, shareholders, directors, managers, officers or employees, shall be expressly or impliedly restricted or prohibited solely by virtue of this Agreement or the relationships created hereby from engaging in other activities or business ventures of any kind or character whatsoever and (ii) except as otherwise agreed in writing or by written Company policy, each Member and Manager of the Company, and their respective affiliates, partners, members, shareholders, directors, managers, officers and employees, shall have the right to conduct, or to possess a direct or indirect ownership interest in, activities and business ventures of every type and description, including activities and business ventures in direct competition with the Company.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.